Targeting fatty acid binding protein (FABP) anandamide transporters - a novel strategy for development of anti-inflammatory and anti-nociceptive drugs.

Targeting fatty acid binding protein (FABP) anandamide transporters - a novel strategy for development of anti-inflammatory and anti-nociceptive drugs.
复制标题

DOI:
10.1371/journal.pone.0050968
复制
发表时间:
2012
期刊:
影响因子:
3.7
通讯作者:
Deutsch DG
Deutsch DG
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Berger WT;Ralph BP;Kaczocha M;Sun J;Balius TE;Rizzo RC;Haj-Dahmane S;Ojima I;Deutsch DG

文献摘要

参考文献

被引文献

相似文献

Fatty acid binding proteins (FABPs), in particular FABP5 and FABP7, have recently been identified by us as intracellular transporters for the endocannabinoid anandamide (AEA). Furthermore, animal studies by others have shown that elevated levels of endocannabinoids resulted in beneficial pharmacological effects on stress, pain and inflammation and also ameliorate the effects of drug withdrawal. Based on these observations, we hypothesized that FABP5 and FABP7 would provide excellent pharmacological targets. Thus, we performed a virtual screening of over one million compounds using DOCK and employed a novel footprint similarity scoring function to identify lead compounds with binding profiles similar to oleic acid, a natural FABP substrate. Forty-eight compounds were purchased based on their footprint similarity scores (FPS) and assayed for biological activity against purified human FABP5 employing a fluorescent displacement-binding assay. Four compounds were found to exhibit approximately 50% inhibition or greater at 10 µM, as good as or better inhibitors of FABP5 than BMS309403, a commercially available inhibitor. The most potent inhibitor, γ-truxillic acid 1-naphthyl ester (ChemDiv 8009-2334), was determined to have Ki value of 1.19±0.01 µM. Accordingly a novel α-truxillic acid 1-naphthyl mono-ester (SB-FI-26) was synthesized and assayed for its inhibitory activity against FABP5, wherein SB-FI-26 exhibited strong binding (Ki 0.93±0.08 µM). Additionally, we found SB-FI-26 to act as a potent anti-nociceptive agent with mild anti-inflammatory activity in mice, which strongly supports our hypothesis that the inhibition of FABPs and subsequent elevation of anandamide is a promising new approach to drug discovery. Truxillic acids and their derivatives were also shown by others to have anti-inflammatory and anti-nociceptive effects in mice and to be the active component of Chinese a herbal medicine (Incarvillea sinensis) used to treat rheumatism and pain in humans. Our results provide a likely mechanism by which these compounds exert their effects.
DOI: 10.1038/nn.2986
发表时间: 2011-11-20
影响因子: 25
作者:
通讯作者: --
DOI: 10.1248/bpb.29.580
发表时间: 2006-03-01
影响因子: 2
作者:
Chi, YM;Nakamura, M;Sakurada, S
通讯作者: Sakurada, S
DOI: 10.1074/jbc.m111.304907
发表时间: 2012-01-27
影响因子: 4.8
作者:
Kaczocha, Martin;Vivieca, Stephanie;Deutsch, Dale G.
通讯作者: Deutsch, Dale G.
DOI: 10.1016/j.bmcl.2006.12.044
发表时间: 2007-06-15
影响因子: 2.7
作者:
Sulsky, Richard;Magnin, David R.;Robl, Jeffrey A.
通讯作者: Robl, Jeffrey A.
DOI: 10.1016/j.bmcl.2012.02.017
发表时间: 2012-04-15
影响因子: 2.7
作者:
Holden, Patrick M.;Kaur, Harmeet;Goyal, Rashi;Gochin, Miriam;Rizzo, Robert C.
通讯作者: Rizzo, Robert C.